| 1. |
- Aronsson, Helena, et al.
(författare)
-
Mellangrödor i växtföljden - för kolinlagring och effektivt kväveutnyttjande
- 2023
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- Rapporten beskriver mellangrödors funktion för kolinlagring i jordbruksmark i relation till andra funktioner och miljörisker. Den består av en kunskapsgenomgång, en inventering av data från fältförsök samt en sammanfattning av odlares erfarenheter vid en workshop. Vår definition av mellangröda är: En gröda som har sin huvudsakliga tillväxt mellan två huvudgrödor, och där syftet med att odla mellangrödan kan variera.Mellangrödan ger kolinlagring, särskilt rötternaKolinlagringen av en mellangröda har uppskattats till ca 320 kg kol i medeltal per ha och år, men variationen är stor. Vi sammanställde resultat från fältförsök med mellangrödor under 30 år. För insådda gräsfånggrödor skiljer sig biomassaproduktionen i medeltal inte så mycket åt mellan olika regioner, medan variationen är större för eftersådda mellangrödor. Det saknas kunskap för att kunna ge konkreta råd om hur artval och jordbearbetningsstrategier m.m. för mellangröda kan användas för att optimera stabiliseringsprocesserna för kol i marken. Mellangrödans rötter bidrar med ca 2,5 gånger större inlagring än den ovanjordiska grönmassan. Mätningar vi funnit visar en stor variation i viktförhållandet mellan skott och rot, som beror på arters variation, men också på osäkerheter i provtagning och metoder.Utmaningar för odlarnaBåde försök och odlares erfarenheter vittnar om utmaningar med sådd av mellangrödor efter skörd, särskilt på jordar med hög lerhalt. Det handlar om att hinna så direkt efter huvudgrödans skörd för att lyckas med etableringen och för att utnyttja hösten för tillväxt. Att ge sådd av mellangrödan lika hög prioritet som en huvudgröda var ett råd som erfarna odlare poängterade vid en workshop. Det finns olika tankesätt och strategier kring val av arter, beroende på syftet med mellangrödan. Genom artblandningar kan man också kombinera funktioner. Det finns inga tydliga råd för arter som särskilt främjar kolinlagring utan det viktigaste är stor tillväxt, hög kol-kväve-kvot (C/N-kvot), stor rotbiomassa samt baljväxtinslag. Hushållning med kvävet En nordisk sammanställning visade att mellangrödor i medeltal minskade kväveläckaget med drygt 40 %. Tidpunkt för nedbrukning eller kemisk avdödning är metoder för att styra återmineraliseringen och kväveverkan i nästa gröda. För frostkänsliga mellangrödor med låg C/N-kvot finns en risk att kvävet frigörs så snabbt att det hinner utlakas innan våren. Under sådana förhållanden ökar också risken för lustgasemissioner. Mer kunskap behövs om hur kväveomsättning påverkas och hur lustgasemissioner kan minimeras, för att kunna anpassa mellangrödesystemen efter olika odlingskrav och klimatets förändring.
|
|
| 2. |
- Barbu, Mikael, et al.
(författare)
-
Dextran- versus crystalloid-based prime in cardiac surgery: A prospective randomized pilot study.
- 2020
-
Ingår i: The Annals of thoracic surgery. - : Elsevier BV. - 1552-6259 .- 0003-4975. ; 110:5, s. 1541-7
-
Tidskriftsartikel (refereegranskat)abstract
- The optimum priming fluid for the cardiopulmonary bypass (CPB) circuit is still debated. We compared a new hyperoncotic priming solution containing dextran 40, which has an electrolyte composition that mimics extracellular fluid, with a standard crystalloid-based prime.Eighty cardiac surgery patients were included in this double-blind randomized single-centre study. The patients were randomized to either a dextran-based prime or a crystalloid prime containing Ringer acetate and mannitol. The primary endpoint was colloid oncotic pressure (COP) in serum during CPB. Secondary endpoints included fluid balance, bleeding and transfusion requirements, pulmonary function, hemolysis, systemic inflammation, and markers of renal, hepatic, myocardial, and brain injury. Blood samples were collected before, during, and after CPB.COP was higher in the dextran group than in the crystalloid prime group on CPB (18.8±2.9 vs. 16.4±2.9 mmHg, p<0.001) and 10 min after CPB (19.2±2.7 vs. 16.8±2.9 mmHg, p<0.001). Patients in the dextran group required less intravenous fluid during CPB (1090±499 vs. 1437±543 ml; p=0.003) and net fluid balance was less positive 12h after surgery (+1,431±741 vs. +1,901±922 ml; p=0.014). Plasma free hemoglobin was significantly lower in the dextran group 2h after CPB (0.18±0.11 vs 0.41±0.33, p=0.001). There were no significant differences in bleeding, transfusion requirements, organ function, systemic inflammation, or brain and myocardial injury markers between the groups at any time point.Our results suggest that a hyperoncotic dextran-based priming solution preserves intraoperative COP compared to crystalloid prime. Larger studies with clinically valid endpoints are necessary to evaluate hyperoncotic prime solutions further.
|
|
| 3. |
- Carlsson, Ylva, 1975, et al.
(författare)
-
Comparing the results from a Swedish pregnancy cohort using data from three automated placental growth factor immunoassay platforms intended for first-trimester preeclampsia prediction.
- 2023
-
Ingår i: Acta Obstetricia et Gynecologica Scandinavica. - : Wiley. - 0001-6349 .- 1600-0412. ; :8, s. 1084-1091
-
Tidskriftsartikel (refereegranskat)abstract
- INTRODUCTION: Risk evaluation for preeclampsia in early pregnancy allows identification of women at high risk. Prediction models for preeclampsia often include circulating concentrations of placental growth factor (PlGF); however, the models are usually limited to a specific PlGF method of analysis. The aim of this study was to compare three different PlGF methods of analysis in a Swedish cohort to assess their convergent validity and appropriateness for use in preeclampsia risk prediction models in the first trimester of pregnancy.MATERIAL AND METHODS: First-trimester blood samples were collected in gestational week 11+0 to 13+6 from 150 pregnant women at Uppsala University Hospital during November 2018 until November 2020. These samples were analyzed using the different PlGF methods from Perkin Elmer, Roche Diagnostics, and Thermo Fisher Scientific.RESULTS: There were strong correlations between the PlGF results obtained with the three methods, but the slopes of the correlations clearly differed from 1.0: PlGFPerkinElmer = 0.553 (95% confidence interval [CI] 0.518-0.588) * PlGFRoche -1.112 (95% CI -2.773 to 0.550); r = 0.966, mean difference -24.6 (95% CI -26.4 to -22.8). PlGFPerkinElmer = 0.673 (95% CI 0.618-0.729) * PlGFThermoFisher -0.199 (95% CI -2.292 to 1.894); r = 0.945, mean difference -13.8 (95% CI -15.1 to -12.6). PlGFRoche = 1.809 (95% CI 1.694-1.923) * PlGFPerkinElmer +2.010 (95% CI -0.877 to 4.897); r = 0.966, mean difference 24.6 (95% CI 22.8-26.4). PlGFRoche = 1.237 (95% CI 1.113-1.361) * PlGFThermoFisher +0.840 (95% CI -3.684 to 5.363); r = 0.937, mean difference 10.8 (95% CI 9.4-12.1). PlGFThermoFisher = 1.485 (95% CI 1.363-1.607) * PlGFPerkinElmer +0.296 (95% CI -2.784 to 3.375); r = 0.945, mean difference 13.8 (95% CI 12.6-15.1). PlGFThermoFisher = 0.808 (95% CI 0.726-0.891) * PlGFRoche -0.679 (95% CI -4.456 to 3.099); r = 0.937, mean difference -10.8 (95% CI -12.1 to -9.4).CONCLUSION: The three PlGF methods have different calibrations. This is most likely due to the lack of an internationally accepted reference material for PlGF. Despite different calibrations, the Deming regression analysis indicated good agreement between the three methods, which suggests that results from one method may be converted to the others and hence used in first-trimester prediction models for preeclampsia.
|
|
| 4. |
- Hansson-Forman, Katarina, 1991-, et al.
(författare)
-
What influences hunting participation of potential new hunters? : Qualitative insights from Sweden
- 2020
-
Ingår i: Wildlife Biology. - : The Nordic Board for Wildlife Research (NKV). - 0909-6396 .- 1903-220X. ; 2020:4
-
Tidskriftsartikel (refereegranskat)abstract
- Hunting, an activity conceptualized as part of wildlife management partnership between the state, landowners and hunting communities, is increasingly challenged by a decreasing hunter base. This has ecological, economic and socio-cultural consequences, and the issue of hunter recruitment deserves more scholarly and political attention. In Sweden, the number of individuals taking a hunting proficiency test is high even though the number of hunters has declined during the last few decades although with a recovery the last 12 months, indicating an under-utilized source of potential new hunters. We explore in an interview study with potential new hunters in Sweden what factors affect and motivate individuals to take the hunter proficiency test and to hunt. Our thematic analysis identifies structural, institutional and individual factors influencing hunting participation, such as social networks and access to land, rendering two ideal types of new hunters. We offer suggestions to help curb the negative trend of declining hunter numbers and we identify research gaps for future studies to address.
|
|
| 5. |
- Hansson, Göran K., et al.
(författare)
-
Developing a vaccine against atherosclerosis
- 2020
-
Ingår i: Nature Reviews Cardiology. - : Springer Science and Business Media LLC. - 1759-5002 .- 1759-5010. ; 17:8, s. 451-452
-
Tidskriftsartikel (refereegranskat)
|
|
| 6. |
- Holmen, A., et al.
(författare)
-
Whole Blood Adsorber During CPB and Need for Vasoactive Treatment After Valve Surgery in Acute Endocarditis: A Randomized Controlled Study
- 2022
-
Ingår i: Journal of Cardiothoracic and Vascular Anesthesia. - : Elsevier BV. - 1053-0770. ; 36:8, s. 3015-3020
-
Tidskriftsartikel (refereegranskat)abstract
- Objectives: Patients with endocarditis requiring urgent valvular surgery with cardiopulmonary bypass are at a high risk of developing systemic inflammatory response syndrome and septic shock, necessitating intensive use of vasopressors after surgery. The use of a cytokine hemoadsorber (CytoSorb, CytoSorbents Europe GmbH, Germany) during cardiac surgery has been suggested to reduce the risk of inflammatory activation. The study authors hypothesized that adding a cytokine adsorber would reduce cytokine burden, which would translate into improved hemodynamic stability. Design: A randomized, controlled, nonblinded clinical trial. Setting: At a university hospital, tertiary referral center. Participants: Nineteen patients with endocarditis undergoing valve surgery. Intervention: A cytokine hemoadsorber integrated into the cardiopulmonary bypass circuit. Measurements and Main Results: The accumulated norepinephrine dose in the intervention group was half or less at all postoperative time points compared to the control group, although it did not reach statistical significance; at 24 and 48 hours (median 36 [25-75 percentiles; 12-57] mu g v 114 [25-559] mu g, p = 0.11 and 36 [12-99] mu g v 261 [25-689] mu g, p = 0.09). There was no significant difference in chest tube output, but there was a significantly lower need for the transfusion of red blood cells (285 [0-657] mL v 1,940 [883-2,148] mL, p = 0.03). Conclusions: There was no statistically significant difference between the groups with regard to vasopressor use after surgery for endocarditis with the use of a cytokine hemoadsorber during cardiopulmonary bypass. Additional, larger randomized controlled trials are needed to definitely assess the potential effect. (C) 2022 Elsevier Inc. All rights reserved.
|
|
| 7. |
- Jönsson, Göran, et al.
(författare)
-
Increased serum bactericidal activity of autologous serum in C2 deficiency after vaccination against Haemophilus influenzae type b, and further support for an MBL-dependent C2 bypass mechanism
- 2021
-
Ingår i: Vaccine. - : Elsevier BV. - 0264-410X. ; 39:8, s. 1297-1302
-
Tidskriftsartikel (refereegranskat)abstract
- Deficiencies of C2 and other components of the classical pathway of complement are associated with increased risk of infections with encapsulated bacteria, such as Haemophilus (H.) influenzae. Defense against H. influenzae is dependent on specific antibodies and complement, which mediate serum bactericidal activity (SBA) and opsonization. Due to lack of normal classical and lectin complement pathway function in C2 deficiency (C2D), SBA would have to depend either on the alternative pathway or on C2 bypass mechanisms. Here we studied SBA against H. influenzae type b (Hib) before and after vaccination in a group of C2-deficient persons, as the bactericidal capacity of antibodies in autologous complement in relation to vaccination has not been investigated at group level in C2D. Sera from 22 persons with C2D and 26 healthy controls were available. Out of these, 18 persons with C2D and all controls had been vaccinated with Act-HIB®. SBA against Hib bacteria was analyzed with autologous serum as the only complement source. Antibodies to Hib capsular polysaccharide had been analyzed previously. Concentrations of mannose-binding lectin (MBL) and other complement components were measured in serum. SBA of both C2-deficient persons and controls was significantly more efficient after vaccination (p = 0.002 and p < 0.0001, respectively). After vaccination, all but two C2-deficient sera and one control serum showed sufficient SBA (<50% surviving bacteria). Before vaccination, SBA of C2-deficient sera was negatively correlated to serum concentrations of MBL (lower proportion of surviving bacteria with higher MBL concentration; r = −0.55, p = 0.008). After vaccination, SBA of C2-deficient sera was negatively correlated to serum concentrations of IgG Hib antibodies (r = −0.56, p = 0.01). In conclusion, SBA against Hib in autologous serum is increased after vaccination in persons with C2D. In unvaccinated C2-deficient persons SBA was correlated to MBL concentration, providing further support for an MBL-dependent C2 bypass mechanism operating in C2D.
|
|
| 8. |
- Mennander, Ari A, et al.
(författare)
-
History of cancer and survival after coronary artery bypass grafting: Experiences from the SWEDEHEART registry
- 2020
-
Ingår i: The Journal of thoracic and cardiovascular surgery. - : Elsevier BV. - 1097-685X .- 0022-5223. ; 164:1, s. 107-114
-
Tidskriftsartikel (refereegranskat)abstract
- To explore the currently unknown association between history of cancer at the time of coronary artery bypass grafting (CABG) and long-term survival.All patients (n=82,137) undergoing isolated first-time CABG in Sweden during 1997-2015 were included in this retrospective population-based cohort study. Individual patient data from the SWEDEHEART registry and 4 other mandatory nationwide health care registries were merged. Multivariable Cox proportional hazards regression and competing risk models adjusted for age and gender were used to assess associations between history of cancer, and long-term all-cause, cardiovascular and cancer mortality. Median follow-up was 9.0years (interquartile range, 4.8-13.1).Altogether, 6819 (8.3%) of the patients had a history of cancer. The annual prevalence increased from 3.8% in 1997 to 14.8% in 2015. Patients with a history of cancer were older (72 vs 66years; P<.001) and had more comorbidities. Long-term all-cause mortality was significantly greater in patients with a history of cancer (45.7% vs 22.9% at 10years; adjusted hazard ratio, 1.33; 95% confidence interval [CI], 1.28-1.38, P<.001). According to the competing risk models, history of cancer was associated with an increased risk for cancer death (subdistribution hazard ratio, 2.45; 95% CI, 2.28-2.63, P<.001) but not cardiovascular death (subdistribution hazard ratio, 0.88; 95% CI, 0.83-0.94, P<.001).The proportion of patients undergoing CABG with a history of cancer has increased over time. History of cancer at the time of surgery is associated with increased cancer deaths over time but not cardiovascular deaths. The same cardiovascular prognosis after CABG can be expected regardless of cancer history.
|
|
| 9. |
- Nahi, Hareth, et al.
(författare)
-
Burden of Treatment-Induced Peripheral Neuropathy in Patients with Multiple Myeloma in Sweden
- 2021
-
Ingår i: Acta Haematologica. - : S. Karger AG. - 0001-5792 .- 1421-9662. ; 144:5, s. 519-527
-
Tidskriftsartikel (refereegranskat)abstract
- Introduction: Treatment-induced peripheral neuropathy (TIPN) is a complication of multiple myeloma (MM) treatment. Objective: This real-world, retrospective study used electronic medical record (EMR) data from 3 Swedish clinics to assess the occurrence and economic burden of TIPN in patients with MM. Methods: Eligible patients had an MM diagnosis in the Swedish Cancer Registry between 2006 and 2015 and initiated treatment during that period. Follow-up was until last EMR visit, death, or study end (April 2017). The current analyses included patients receiving bortezomib, lenalidomide, carfilzomib, or thalidomide at any treatment line. To discern healthcare resource utilization (HCRU) and costs associated with TIPN from other causes, patients with TIPN were matched with those without on baseline characteristics, treatment, and line of therapy. All analyses were descriptive. Results: Overall, 457 patients were included; 102 (22%) experienced TIPN. Patients experiencing TIPN during first-line treatment mostly received bortezomib-based regimens (n = 48/57 [84%]); those with TIPN during second- A nd third/fourth-line treatment mostly received lenalidomide/thalidomide-based regimens (19/31 [61%], 8/14 [57%], respectively). Patients with TIPN had higher HCRU/costs than those without TIPN (mean differences in hospital outpatient visits: 5.2, p = 0.0031; total costs per patient-year: EUR 17,183, p = 0.0007). Conclusions: Effective MM treatments associated with a reduced incidence of TIPN could result in decreased healthcare expenditure.
|
|
| 10. |
- Nilsson, Jan, et al.
(författare)
-
Vaccination Strategies and Immune Modulation of Atherosclerosis
- 2020
-
Ingår i: Circulation Research. - 0009-7330 .- 1524-4571. ; 126:9, s. 1281-1296
-
Tidskriftsartikel (refereegranskat)abstract
- Adaptive as well as innate immune responses contribute to the development of atherosclerosis. Studies performed in experimental animals have revealed that some of these immune responses are protective while others contribute to the progression of disease. These observations suggest that it may be possible to develop novel therapies for cardiovascular disease by selectively modulating such atheroprotective and proatherogenic immunity. Recent advances in cancer treatment using immune check inhibitors and CAR (chimeric antigen receptor) T-cell therapy serve as excellent examples of the possibilities of targeting the immune system to combat disease. LDL (low-density lipoprotein) that has accumulated in the artery wall is a key autoantigen in atherosclerosis, and activation of antigen-specific T helper 1-type T cells is thought to fuel plaque inflammation. Studies aiming to prove this concept by immunizing experimental animals with oxidized LDL particles unexpectedly resulted in activation of atheroprotective immunity involving regulatory T cells. This prompted several research groups to try to develop vaccines against atherosclerosis. In this review, we will discuss the experimental and clinical data supporting the possibility of developing immune-based therapies for lowering cardiovascular risk. We will also summarize ongoing clinical studies and discuss the challenges associated with developing an effective and safe atherosclerosis vaccine.
|
|
| 11. |
- Olovsson, Tord Göran, 1967-, et al.
(författare)
-
På väg mot kollektivt lärande – inom ramen för samverkan mellan skola och universitet
- 2024
-
Ingår i: Forskning och utveckling i förskola och skola (Fufos). - Piteå : Utbildningsförvaltningen, Piteå kommun. - 2004-3635. ; 3:1, s. 62-81
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Artikeln, författad av forskare, förstelärare och skolledande personal, bygger på ett samverkansprojekt med målet att utveckla en gymnasieskolas kollektiva lärande. Artikeln syftar till att bidra till förståelse av vad ett sådant utvecklingsarbete kan innebära. Metoder som användes var enkätundersökning och intervjuer. Dataanalys genomfördes med stöd av tematisk analys i olika steg (jfr Braun & Clarke, 2006) och teoretiska begrepp som kollektivt och kollegialt lärande (Larsson, 2018) samt olika former av begreppet tillit (Jederlund, 2019). Resultaten visar att förstelärare som leder utvecklingsarbete påverkas av tidigare erfarenheter från utvecklingsarbete och att det är viktigt att lärare som medverkar känner tillit till enskilda kollegor, till den större grupp de ingår i samt till processen bakom utvecklingsarbetet. Samverkansprojektet bidrog till skapande av strukturer för fortsatt utveckling samt till insikt om att utvecklingsarbete främst handlar om att utveckla arbetssätt som är lämpliga för den egna verksamheten.
|
|
| 12. |
- Recktenwald, Christian V, et al.
(författare)
-
The structure of the second CysD domain of MUC2 and role in mucin organization by transglutaminase-based cross-linking
- 2024
-
Ingår i: Cell Reports. - 2211-1247. ; 43
-
Tidskriftsartikel (refereegranskat)abstract
- The MUC2 mucin protects the colonic epithelium by a two-layered mucus with an inner attached bacteria-free layer and an outer layer harboring commensal bacteria. CysD domains are 100 amino-acid-long sequences containing 10 cysteines that separate highly O-glycosylated proline, threonine, serine (PTS) regions in mucins. The structure of the second CysD, CysD2, of MUC2 is now solved by nuclear magnetic resonance. CysD2 shows a stable stalk region predicted to be partly covered by adjacent O-glycans attached to neighboring PTS sequences, whereas the CysD2 tip with three flexible loops is suggested to be well exposed. It shows transient dimer interactions at acidic pH, weakened at physiological pH. This transient interaction can be stabilized in vitro and in vivo by transglutaminase 3-catalyzed isopeptide bonds, preferring a specific glutamine residue on one flexible loop. This covalent dimer is modeled suggesting that CysD domains act as connecting hubs for covalent stabilization of mucins to form a protective mucus.
|
|
| 13. |
- van der Zwaan, Irès
(författare)
-
Characterisation of an in vitro dissolution method for assessment of novel pulmonary drug delivery systems : With a focus on controlled release systems
- 2023
-
Doktorsavhandling (övrigt vetenskapligt/konstnärligt)abstract
- Pulmonary drug delivery has been used for decades to treat local diseases like asthma. When using the pulmonary route to deliver drugs, several important lung features are being used, such as a large surface area available for absorption, high organ vascularization, and a thin blood-alveolar barrier. Pulmonary drug delivery systems on the market are formulations with a rapid release, which leads to a high drug concentration initially and a prompt decline in concentration shortly thereafter. This could cause unfavourable adverse effects or toxicity to the lung tissue at the onset of the release and could also result in decreased efficacy. To overcome these challenges, there is a need to develop controlled release drug delivery systems to improve the therapeutic effectiveness of inhaled drugs. When a drug is inhaled, the drug particles will deposit in the lung, and the drug needs to dissolve in the lung fluids before the drug is available for uptake locally or in the systemic circulation. The absorption inhaled drug thus depends on the dissolution of the drug particles in the lung fluid. As a result, it could be possible to prolong the duration of the drug effect, by prolonging the time it takes for the dissolution of the drug particles. Due to this, in vitro methods analysing the dissolution of the drug particles in the lung are of high relevance for the development of novel pulmonary drug delivery systems. It is therefore of high importance that the dissolution profiles that are measured are well understood. The overall aim of this thesis was to evaluate and characterise an in vitro dissolution method (Transwell system) for assessment of novel pulmonary drug delivery systems, with a focus on future controlled release systems. A developed mechanistic model was used to analyse experimental dissolution data and to predict which process was the rate limiting step in the obtained profiles. The developed mechanistic model provided the same rank order as the Weibull fit, however the model provided additional detailed understanding of the used dissolution process and setup. In addition, two novel controlled release drug delivery systems, mesoporous silica particles and hyaluronic based hydrogels, were successfully analysed using this in vitro dissolution system. Both delivery systems showed a promising aerosolization and control over the release profiles. Finally, the micellar contribution to diffusion of poorly soluble inhaled drugs during in vitro dissolution was defined and validated using the obtained in vitro dissolution profiles. Physiologically based biopharmaceutics modelling tools were successfully established for Bud, BDP and FP using the diffusivity values taking into account the micellar contribution of the surfactant.
|
|
| 14. |
- Vidarsdottir, Linda, et al.
(författare)
-
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
- 2021
-
Ingår i: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 11:1
-
Tidskriftsartikel (refereegranskat)abstract
- BRAF inhibitors (BRAFi) selectively target oncogenic BRAFV600E/K and are effective in 80% of advanced cutaneous malignant melanoma cases carrying the V600 mutation. However, the development of drug resistance limits their clinical efficacy. Better characterization of the underlying molecular processes is needed to further improve treatments. We previously demonstrated that transcription of PTEN is negatively regulated by the PTEN pseudogene antisense RNA, PTENP1-AS, and here we investigated the impact of this transcript on clinical outcome and BRAFi resistance in melanoma. We observed that increased expression levels of PTENP1-AS in BRAFi resistant cells associated with enrichment of EZH2 and H3K27me3 at the PTEN promoter, consequently reducing the expression levels of PTEN. Further, we showed that targeting of the PTENP1-AS transcript sensitized resistant cells to BRAFi treatment and that high expression of PTENP1-AS in stage III melanoma correlated with poor survival. Collectively, the data presented here show that PTENP1-AS is a promising target for re-sensitizing cells to BRAFi and also a possible prognostic marker for clinical outcome in stage III melanoma.
|
|
| 15. |
- Walinder, Göran, et al.
(författare)
-
Outcome and characteristics of non-measurable myeloma : A cohort study with population-based data from the Swedish Myeloma Registry
- 2020
-
Ingår i: European Journal of Haematology. - : Wiley. - 0902-4441 .- 1600-0609. ; 104:5, s. 376-382
-
Tidskriftsartikel (refereegranskat)abstract
- Objective We describe survival in patients with oligo- and non-secretory multiple myeloma (MM). We refer to the whole group as non-measurable MM and compare it with secretory MM. Methods Oligo-secretory MM was defined as M protein in serum <10 g/L and M protein in urine <200 measured as mg/day, mg/liter or mg/mmol creatinine. If patients had no M protein, they were defined as non-secretory. The groups were also subdivided by Free Light Chains (SFLC) level and ratio. Results Out of 4325 patients with symptomatic MM in the Swedish Myeloma Registry during 2008-2016 eligible for the study, 389 patients (9%) had non-measurable MM. Out of these, 253 patients (6%) had oligo-secretory and 136 (3%) had non-secretory MM. Median survival for secretory MM was 42.7 months, non-measurable MM 40.2 months, oligo-secretory MM 38.6 months, and non-secretory MM 44.6 months. Difference in overall observed survival was non-significant for all groups when compared with secretory MM. Within non-secretory MM, stem cell transplantation (SCT), 95% being auto-SCT, was significant for superior survival in multivariate analysis (HR 0.048. P = .0015). Conclusion In this population-based study, we found no difference in survival between oligo- or non-secretory MM when compared with secretory MM. SCT appears to be important also for patients with non-secretory disease.
|
|
| 16. |
- Wålinder, Göran, et al.
(författare)
-
Regional differences in treatment and outcome for myeloma patients in Sweden : A population based Swedish myeloma register study
- 2022
-
Ingår i: Cancer Reports. - : Wiley. - 2573-8348. ; 5:11
-
Tidskriftsartikel (refereegranskat)abstract
- Background: We wanted to evaluate if health care for multiple myeloma (MM) patients is equal in different regions of Sweden. Aim: To study differences in survival for MM depending on health care region and early use of modern treatment. Methods and results: Data from the Swedish Myeloma Register from patients diagnosed between 2008 and 2017 was used. Cohorts were defined by the six healthcare regions (labeled A–F) in Sweden and modern initial treatment was defined as including certain drug combinations. To adjust for time to treatment bias, survival analyses were performed also for patients alive 6 months after diagnosis. In all treated MM patients (n = 5326), we observed a superior overall survival (OS) for region A compared to all other regions (p <.01 for all respectively). After adjusting for time to treatment there was also a superior survival in the region with highest use of modern initial treatment (region A) compared to the regions defined in the study as having intermediate and low use (p <.01 for both). In patients receiving autologous stem cell transplantation (ASCT) a superior survival was observed for region A compared to all regions besides region B. Similar results were seen when adjusting for a time to treatment bias. In patients not receiving ASCT, 75 years or older and adjusted for time to treatment bias, a difference was noted only between region A and E (log rank p =.04, HR 1.2, CI 1.00–1.44, p =.06). In multivariate analyses including age, international staging system stage and time period of diagnosis, differences in survival remained for patients receiving ASCT between region A versus C, D, E and F (p =.01, p <.01, p <.01, p =.03). Conclusion: We observed a superior survival in region A for patients receiving ASCT. Explanations may be higher usage of modern initial treatment or regional residual confounding. For patients not receiving ASCT, 75 years or older, differences in survival could be adjusted for.
|
|
